WaveMan
WaveMan · Company
CADL · Candel Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CADL Candel Therapeutics (CADL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001841387
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
104
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $193.8K priced

What the filings say about CADL

Insiders, 180 days
-$3.6M net sold
3 sellers · 40% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.5M
2 notices

Candel Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Candel Therapeutics, Inc. insiders sold a net $3.6M of stock across 65 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Tak Paul Peter
Chief Executive Officer
SELL
2026-09-11 SEC
59,379
$620.9K
-22.7%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (3 buys, 8 sales), the last on Sep 10, 2026.
  • +5.3% median (+15.5% mean) 90-day return after 3 previous buys.
  • The trade is 52.4% of the 113,321 shares held after it.
  • 1 other insider sold within 30 days.
  • 104 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Tak Paul Peter sold about $620.9K of CADL under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 104 funds added in the latest 13F quarter.
Tak Paul Peter
Chief Executive Officer
SELL
2026-09-11 SECtraded 2026-09-10
220,866
$2.5M
-22.7%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (3 buys, 7 sales), the last on Mar 19, 2025.
  • +5.3% median (+15.5% mean) 90-day return after 3 previous buys.
  • The trade is 127.9% of the 172,700 shares held after it.
  • 1 other insider sold within 30 days.
  • 104 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Tak Paul Peter sold about $2.5M of CADL under a 10b5-1 plan on Sep 10, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 104 funds added in the latest 13F quarter.
Tyagarajan Seshu
Chief Technology Officer
SELL
2026-08-19 SECtraded 2026-08-17
7,000
$84.0K
-33.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Jun 29, 2026.
  • -5.5% median (-5.5% mean) 90-day return after 2 previous buys.
  • The trade is 9.1% of the 76,865 shares held after it.
  • 1 other insider sold within 30 days.
  • 104 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Tyagarajan Seshu sold about $84.0K of CADL on Aug 17, 2026; 1 other insider sold within 30 days and 104 funds added in the latest 13F quarter.
Barone Francesca
Chief Scientific Officer
SELL
2026-07-01 SECtraded 2026-06-29
23,447
$235.8K
-16.1%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on Mar 18, 2025.
  • The trade is 30.3% of the 77,362 shares held after it.
  • 1 other insider sold within 30 days.
  • 104 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Barone Francesca sold about $235.8K of CADL on Jun 29, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 104 funds added in the latest 13F quarter.
Tyagarajan Seshu
Chief Technology Officer
SELL
2026-07-01 SECtraded 2026-06-29
7,000
$70.2K
-16.1%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (2 buys, 6 sales), the last on Mar 17, 2025.
  • -5.5% median (-5.5% mean) 90-day return after 2 previous buys.
  • The trade is 8.3% of the 83,865 shares held after it.
  • 1 other insider sold within 30 days.
  • 104 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Tyagarajan Seshu sold about $70.2K of CADL on Jun 29, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 104 funds added in the latest 13F quarter.
65 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 60 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.6M over 180 days
-$3.2M over 90 days
below 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
104 funds bought in last quarter
more than 71% of Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
21.6% of the float short (float per yahoo 2026-10-26) · 11.2 days to cover · settled 2026-09-30
more than 90% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CADL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+55.4%12M
-17%+42%+100%+159%2025-102025-122026-022026-042026-062026-082026-10 2026-02-23 · Manning Paul B bought $3.0M2026-09-10 · Tak Paul Peter sold $2.5M2026-09-11 · Tak Paul Peter sold $620.9K2026-06-29 · Barone Francesca sold $235.8K2026-08-17 · Tyagarajan Seshu sold $84.0K2026-06-29 · Tyagarajan Seshu sold $70.2K2026-09-10 · PAUL PETER TAK filed to sell $3.4M2026-08-17 · SESHU TYAGARAJAN filed to sell $82.0K2026-06-29 · FRANCESCA BARONE filed to sell $229.5K2026-06-29 · SESHU P TYAGARAJAN filed to sell $68.5K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CADL: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
10,990,535 sh
$113.2M
RTW INVESTMENTS, LP
6,422,018 sh
$66.1M
BlackRock, Inc.
4,969,040 sh
$51.2M
STATE STREET CORP
3,549,823 sh
$36.6M
ACORN CAPITAL ADVISORS, LLC
3,497,948 sh
$36.0M

Congress trades in CADL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CADL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
PAUL PETER TAK
Filed 2026-09-10
$3.4M
SESHU TYAGARAJAN
Filed 2026-08-17
$82.0K
FRANCESCA BARONE
Filed 2026-06-29
$229.5K
SESHU P TYAGARAJAN
Filed 2026-06-29
$68.5K

CADL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Life Sciences and Healthcare Fund
$377.8K position · as of 2026-06-30
0.8%
Virtus Biotech Clinical Trials Etf
$363.5K position · as of 2026-07-31
0.8%
Select Biotechnology Portfolio
$40.4M position · as of 2026-05-31
0.8%
ALPS Medical Breakthroughs ETF
$626.6K position · as of 2026-05-31
0.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$20.8M position · as of 2026-06-30
0.2%
PROFUND VP BIOTECHNOLOGY
$92.4K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 1
0 active
5
Phase 2
3 active
2
Phase 3
2 active
What changed recently
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besade
2026-09-16 · Completion moved 2026-08 → 2027-02
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.6M sold by insiders over 180 days, 104 funds added last quarter, $3.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CADL financials

Revenue growth
0.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$124.0K
four quarters, 2022-01-01 to 2022-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$57.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.01x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
-51.54x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Return on equity
-81.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-56.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-50.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$430.8M
market value at close 2026-10-27 on 2026-08-06 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
FCF yield
-9.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$125.0K
Operating income-$48.3M-$33.4M-$38.4M-$34.7M
Net income-$38.2M-$55.2M-$37.9M-$18.8M
EPS (diluted)-0.72-1.74-1.31-0.65
Operating cash flow-$38.3M-$27.0M-$34.2M-$31.4M
Cash$119.7M$102.7M$35.4M$70.1M
Long-term debt$1.0M$1.7M$11.6M$648.0K
SEC XBRL, fiscal years, as known on 2026-10-28

CADL Stock Sonar score 6/7 axes

Find similar shapesCompare

CADL ranks highest on institutional and government (71st percentile) and risk and compliance (47th), and lowest on insider conviction (22nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
43
Inputs
  • Return on equity-81.8% · 38 pct, sector of 545
  • Return on assets-56.4% · 41 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-50.2% · 49 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.01x · 77 pct, sector of 352
  • Cash flow to debt-51.54x · 11 pct, sector of 371
Growth
44
Inputs
  • Revenue growth, YoY+0.0% · 44 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
22
Inputs
  • Net Form 4 buying (codes P and S), 180d-$390K · 44 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
71
Inputs
  • Funds adding, latest quarter104 · 71 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
47
Inputs
  • Short interest, % of float+21.6% · 13 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.2% · 81 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CADL filings, in plain words

Are Candel Therapeutics insiders buying or selling CADL?

In the 180 days to 2026-10-28, Candel Therapeutics insiders were net sellers, a net $3.6M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of CADL?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $3.5M of stock; the latest, by PAUL PETER TAK, was filed 2026-09-10.

Read the full summary

In the 180 days to 2026-10-28, Candel Therapeutics insiders were net sellers of CADL, a net $3.6M across purchases and sales reported on Form 4 by 3 sellers. 40% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $3.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies